Printer Friendly

Hetero wins approval for Generic Sofosbuvir in India.

Hetero, based in Hyderabad, India, has received approval for generic Sofosbuvir Tablets, 400 mg (Gilead's SOVALDI), from the Drug Controller General of India. Hetero has a non-exclusive license agreement with Gilead Sciences, Ireland to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

Hetero will launch Sofosbuvir under its brand Sofovir in India this month with other countries to follow. Hetero has also partnered with other licensee holders to distribute generic Sofosbuvir in India.

"Hepatitis C is a growing public health concern, particularly in developing countries such as India and Hetero is committed to bringing affordable sofosbovir to India" said Vamsi Krishna, director of Hetero.

COPYRIGHT 2015 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:INDUSTRY NEWS
Publication:Contract Pharma
Geographic Code:9INDI
Date:Apr 1, 2015
Previous Article:Emergent inks Ebola Vax contracts.
Next Article:SGS Broadens Solid State Analysis Services.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters